ArticleEmerging microbes & infections2024
Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent
Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mortality risk of carbapenem-resistant hypervirulentFrontiers in public health · 2025Pooled it
- Novel Non-Coding Small sRNA002 Targets the Virulence-Related GenesMicroorganisms · 2026Article
- Resistance development in KPC-producingMicrobiology spectrum · 2026Article
- Transcriptomic correlates of ceftazidime-avibactam collateral sensitivity in tigecycline-resistant NDM-producing enterobacter cloacae complex.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Repeated insertions at positions 261-280 in KPC-2 highlight a ceftazidime-avibactam resistance hotspot.iScience · 2026Article
- The resistance mechanisms and risk factors of carbapenem-resistant Klebsiella pneumoniae to ceftazidime-avibactam.BMC research notes · 2026Article
- Within-host co-evolution of KPC variants: plasmid-mediated dissemination ofMicrobiology spectrum · 2026Article
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- Carbapenem-resistant hypervirulentFrontiers in microbiology · 2026Review
- Emergence of ST11Microbiology spectrum · 2025Article
- Article
- Mobile genetic elements encoding antibiotic resistance genes and virulence genes inFrontiers in microbiology · 2025Review
- Emergence and evolution of rare ST592Frontiers in cellular and infection microbiology · 2025Article
- Evolution of ceftazidime-avibactam resistance driven by variation inFrontiers in cellular and infection microbiology · 2025Article
- Molecular epidemiology of carbapenem-resistant hypervirulentFrontiers in cellular and infection microbiology · 2025Article
- HypervirulentPathogens & immunity · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftazidime-avibactam resistance attributable to the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.